==== Front New Microbes New InfectNew Microbes New InfectNew Microbes and New Infections2052-2975Elsevier S2052-2975(18)30059-310.1016/j.nmni.2018.07.003Original ArticlePathogenicity locus determinants and toxinotyping of Clostridioides difficile isolates recovered from Iranian patients Aliramezani A. 1Talebi M. Talebi_25@yahoo.com9∗Baghani A. 1Hajabdolbaghi M. 2Salehi M. 2Abdollahi A. 3Afhami S. 4Marjani M. 10Golbabaei F. 11Boroumand M.A. 5Sarrafnejad A. 6Yaseri M. 7Ghourchian S. 1Douraghi M. mdouraghi@tums.ac.ir18∗1) Division of Microbiology, Department of Pathobiology, School of Public Health, Tehran, Iran2) Department of Infectious Diseases and Tropical Medicine, Faculty of Medicine, Tehran, Iran3) Department of Pathology, Imam Hospital Complex, Tehran, Iran4) Department of Infectious Diseases, Shariati Hospital, Tehran, Iran5) Department of Pathology, Tehran Heart Center, Tehran, Iran6) Department of Immunology, School of Public Health, Tehran, Iran7) Department of Epidemiology and Biostatistics, School of Public Health, Tehran, Iran8) Food Microbiology Research Center, Tehran University of Medical Sciences, Tehran, Iran9) Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran10) Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran11) Department of Occupational Health, School of Public Health, Medical Sciences, University of Tehran, Tehran, Iran∗ Corresponding authors: M. Talebi, Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran; and M. Douraghi, Division of Microbiology, Department of Pathobiology, School of Public Health, PO Box 14155-6446, Tehran University of Medical Sciences, Tehran, Iran. Talebi_25@yahoo.commdouraghi@tums.ac.ir02 8 2018 9 2018 02 8 2018 25 52 57 13 5 2018 25 6 2018 5 7 2018 © 2018 Published by Elsevier Ltd.2018This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Little is known about the toxin profiles, toxinotypes and variations of toxin Clostridioides difficile C (tcdC) in Iranian C. difficile isolates. A total of 818 stool specimens were obtained from outpatients (n = 45) and hospitalized patients (n = 773) in Tehran, Iran, from 2011 to 2017. The 44 C. difficile isolates were subjected to PCR of toxin C. difficile A (tcdA), toxin C. difficile B (tcdB), tcdA 3′-end deletion, toxinotyping and sequencing of the tcdC gene. Thirty-eight isolates (86.36%) were identified as tcdA and tcdB positive, and the remaining six isolates (13.63%) were nontoxigenic. All tcdA- and tcdB-positive isolates yielded an amplicon of 2535 bp by PCR for the tcdA 3′ end. Fourteen (36.84%), seventeen (44.73%) and seven (18.43%) isolates belonged to wild-type, toxin C. difficile C subclone3 (tcdC-sc3) and tcdC-A genotype of tcdC, respectively. Thirty-one isolates (81.57%) belonged to toxinotype 0, and seven isolates (18.42%) were classified as toxinotype V. This study provides evidence for the circulation of historical and hypervirulent isolates in the healthcare and community settings. Furthermore, it was also demonstrated that the tcdC-A genotype and toxinotype V are not uncommon among Iranian C. difficile isolates. Keywords Clostridioides difficiletcdAtcdBtcdCtoxinotyping ==== Body Introduction Historically known as a primary aetiologic agent of nosocomial antibiotic-associated diarrhoea, Clostridioides difficile has recently emerged in community settings [1], [2], [3]. C. difficile infections are toxin mediated and are manifested clinically as a spectrum of mild to life-threatening symptoms, from diarrhoea to pseudomembranous colitis [4]. An enterotoxin (toxin A, TcdA) and a cytotoxin (toxin B, TcdB) are the main virulence determinants of C. difficile [5]. The cytotoxic activity of TcdB can lead to diarrhoea, while progression of illness and initial damage of colon are attributed to the enteropathy effects of TcdA [6]. Although the majority of toxigenic strains harbour TcdA and TcdB (TcdA positive/TcdB positive), a proportion of strains carry only TcdB (TcdA negative/TcdB positive) [7]. The genes encoding TcdA and TcdB are located on the 19.6 kb pathogenicity locus (PaLoc), which also contains three open reading frames including toxin C. difficile E (tcdE), toxin C. difficile R (tcdR) and tcdC. TcdC plays an important role as negative regulator of TcdA and TcdB production [8]. Various alterations have been found in the PaLoc genes of C. difficile strains throughout the world, and these variations have remarkable consequences on the structure and function of TcdA and TcdC proteins. A notable alteration is the deletion of 1.8 kb within the 3′ end of tcdA gene which gives rise to the formation of TcdA-negative/TcdB-positive C. difficile strains [9]. While such strains are potentially toxigenic, they could not be detected by cytotoxicity assays because truncated TcdA lacks the ligand-binding domain [7]. Changes in the C terminus of TcdA (A3 fragment) and the N terminus of TcdB (B1 fragment) toxins lead to the definition of 34 variants toxinotypes (I to XXXIV). The most important toxinotypes that were isolated from humans are toxinotype 0, III, IV, V and VIII. The nucleotide polymorphisms in tcdC gene including mutations and/or deletions in coding regions may lead to premature stop codons and consequently truncation of the functional TcdC protein. The mutated TcdC might be associated with increased production of TcdA and TcdB, and accordingly the virulence of C. difficile [10]. Little is known about the toxin profiles, toxinotyping, and variations of tcdC in of Iranian C. difficile strains. Therefore, we analysed the toxin profiles and variations in tcdA and tcdC genes of C. difficile strains recovered from patients with diarrhoea. Materials and methods Setting and isolates This study was conducted at the anaerobic bacteriology laboratory affiliated with the School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. A total of 818 stool specimens were obtained from outpatients (n = 45) and hospitalized patients (n = 773). These patients were suspected of having C. difficile–associated diarrhoea and were referred to the anaerobic bacteriology laboratory from 17 referral tertiary hospitals or clinics located in different geographical areas of Tehran, Iran, from 2011 to 2017 (Table 1). After alcohol shock, stools were cultivated on cycloserine cefoxitin fructose agar and were incubated anaerobically at 37°C for 48 hours. The suspected colonies were identified as C. difficile by colony morphology, specific horse odor, Gram staining and proline–aminopeptidase test [11]. PCR assays Genomic DNA extraction of C. difficile isolates was done using Chelex 100 (Bio-Rad, Hercules, CA, USA) [12]. For molecular identification of C. difficile isolates, we used gene-specific primers targeting C. difficile housekeeping genes including triose phosphate isomerase (tpi), glutamate dehydrogenase (gluD), C. difficile upstream 2 (cdu2) and C. difficile downstream 3 (cdd3) genes [13], [14], [15]. C. difficile isolates were also screened for toxin A (tcdA) and toxin B (tcdB) genes [15], [16]. To confirm complete absence of PaLoc, all tcdA- and tcdB-negative strains were tested with PCR using Lok1-Lok3 primers [17]. In addition, tcdA 3′ end (tcdA3′) deletion analysis was performed using NK9 and NKV011 primers [18]. The entire tcdC gene of isolates was amplified using C1 and C2 primers [16], and subsequently the PCR products were subjected to sequencing. Toxinotyping All tcdA- and tcdB-positive isolates were subjected to toxinotyping using A3 and B1 primers that were previously described [19]. Toxigenic culture The toxigenic culture of C. difficile isolates was performed as follows: three to five colonies of a pure culture of bacteria were subcultured on brain–heart infusion broth and incubated anaerobically for 3 to 5 days at 37°C. After centrifugation and filtration, brain–heart infusion supernatant containing toxin was added to a 96-well microplate containing 104 Vero cell line. After examination of the cell line at 24 and 48 hours under 5% CO2 at 37°C incubation conditions, cytopathic effects were recorded if 50% or more of the Vero cells were rounded [20]. Nucleotide sequence accession number The nucleotide sequences of tcdC gene variants including wild type, truncated variant tcdC-A allele and tcdC-sc3 allele were deposited in GenBank under the accession numbers, indicated in Table 2. Results Of 818 stool samples from outpatients and hospitalized patients, 44 isolates (5.37%) were identified as C. difficile based on detection of tpi, gluD, cdu-2 or cdd-3 (Table 1). Mean and standard deviation of patient age was 53.89 ± 22.44 years. Of 44 isolates, 38 (86.36%) were tcdA and tcdB positive and the remaining 6 (13.63%) isolates were tcdA and tcdB negative and nontoxigenic. All tcdA- and tcdB-negative isolates were positive in PCR reaction using Lok1-Lok3 primers and had 769 bp amplicon (Table 1).Table 1 Genetic profiles and molecular characteristic of Clostridioides difficile isolates Table 1No. Strain Year of isolation Sourcea cdu2/tpi/cdd3/gluD tcdA/tcdB Lok1/Lok3 tcdA 3′ size (bp) tcdC tcdC deletion (bp) tcdC stop codon at 184 bp CPE Toxinotype 1 PC002 2014 H +/+/+/+ +/+ − 2535 + 39 + + V 2 PC004 2014 H +/+/+/+ +/+ − 3100b + − − + 0 3 PC006 2014 H +/+/+/+ +/+ − 2535 + − − + V 4 PC008 2014 H −/+/+/+ +/+ − 3100b + 39 + + 0 5 PC009 2014 H +/+/+/+ +/+ − 3100b + 39 + + 0 6 PC010 2014 H +/+/+/+ +/+ − 2535 + − − + V 7 PC020 2014 H +/+/+/+ +/+ − 2535 + − − + 0 8 PC021 2014 H +/+/+/+ +/+ − 2535 + − − + 0 9 PC024 2014 H +/+/+/+ +/+ − 3100b + − − + 0 10 PC028 2015 H +/+/+/+ +/+ − 2535 + − − + 0 11 PC035 2015 H +/+/+/+ +/+ − 2535 + − − + 0 12 PC036 2015 H +/+/+/+ +/+ − 2535 + − − + 0 13 PC048 2015 H +/+/+/+ −/− + — − − − − - 14 PC049 2015 H +/+/+/+ +/+ − 2535 + − − + 0 15 PC054 2015 H +/+/+/+ +/+ − 2535 + − − + 0 16 PC056 2015 H +/+/+/+ +/+ − 2535 + − − + 0 17 PC062 2015 H +/+/+/+ +/+ − 2535 + 39 + + V 18 PC063 2015 O +/+/+/+ +/+ − 2535 + − − + 0 19 PC066 2015 H +/+/+/+ +/+ − 2535 + − − + 0 20 PC069 2016 O −/+/+/+ +/+ − 2535 + 39 + + V 21 PC071 2011 H +/+/+/+ +/+ − 2535 + − − + 0 22 PC073 2012 H +/+/+/+ −/− + — − − − − - 23 PC074 2011 H +/+/+/+ +/+ − 2535 + − − + 0 24 PC075 2011 H +/+/+/+ −/− + — − − − − - 25 PC080 2016 H +/+/+/+ −/− + — − − − − - 26 PC087 2016 H −/+/+/+ +/+ − 2535 + − − + 0 27 PC089 2016 H −/+/+/+ +/+ − 2535 + − − + 0 28 PC091b 2016 H +/+/+/+ −/− + — − − − − - 29 PC092b 2016 H −/+/+/+ +/+ − 2535 + − − + 0 30 PC096 2016 H −/+/+/+ +/+ − 2535 + 39 + + V 31 PC098 2016 H +/+/+/+ +/+ − 2535 + − − + 0 32 PC101 2016 H +/+/+/+ +/+ − 2535 + − − + 0 33 PC102 2016 H +/+/+/+ −/− + — − − − − - 34 PC103 2016 H +/+/+/+ +/+ − 2535 + − − + 0 35 PC106 2016 H +/+/+/+ +/+ − 2535 + 39 + + V 36 PC107 2016 H +/+/+/+ +/+ − 2535 + − − + 0 37 PC111 2016 H +/+/+/− +/+ − 2535 + − − + 0 38 PC112 2016 H +/+/+/+ +/+ − 2535 + − − + 0 39 PC113 2016 H +/+/+/− +/+ − 2535 + − − + 0 40 PC114 2016 H +/+/+/+ +/+ − 2535 + − − + 0 41 PC115 2016 H +/+/+/+ +/+ − 2535 + − − + 0 42 PC116 2016 H +/+/+/+ +/+ − 2535 + − − + 0 43 PC117 2016 H +/+/+/+ +/+ − 2535 + − − + 0 44 PC118 2017 H +/+/+/+ +/+ − 2535 + − − + 0 a Hospitalized patients (H) or outpatients (O). b Amplicon was obtained using A3C and A4N primers [19]. Of the 38 tcdA- and tcdB-positive isolates, all isolates yielded an amplicon of 2535 bp by PCR amplification for the tcdA 3′ end, thus confirming no deletion at this region. Using NK9 and NKV011 primers, six isolates that were tcdA and tcdB negative also were negative in tcdA 3′-end analysis. Of 38 toxigenic isolates, 31 isolates (81.57%) belonged to toxinotype 0, and 7 (18.42%) were classified as toxinotype V (Table 1). Among the toxigenic isolates, 14 C. difficile isolates (36.84%) had no deletion in tcdC sequences and were assigned to the wild-type tcdC genotype. Seventeen isolates (44.73%) contained a G → T transition at nucleotide 148 and belonged to tcdC-sc3 genotype. Seven isolates (18.43%) had deletion of 39 bp and also a C → T transition at nucleotide 184, and represented the tcdC-A genotype. The latter transition is proposed to result in truncation of the TcdC protein (Table 2).Table 2 tcdC genotypes of Clostridioides difficile isolates Table 2No. Strain Mutation (nucleic acid residues) tcdC genotype GenBank accession no. 1 PC002 G → T (53)/A → T (117)/C → T (120)/C → T (183)/C → T (184) (stop codon)/A → G (330)/G → T (430)/A → C (516)/T → A (558) (stop codon)/T → A (585)/T → C (660)/39bp deletion (341–379) tcdC-A MG675257 2 PC004 G → T (148) tcdC-sc3 MG675248 3 PC006 G → T (148) tcdC-sc3 MG675249 4 PC008 — Wild type MG675253 5 PC009 G → T (53)/A → T (117)/C → T (120)/C → T (183)/C → T (184) (stop codon)/A → G (330)/G → T (430)/A → C (516)/T → A (558) (stop codon)/T → A (585)/T → C (660)/39bp deletion (341–379) tcdC-A MG675258 6 PC010 G → T (53)/A → T (117)/C → T (120)/C → T (183)/C → T (184) (stop codon)/A → G (330)/G → T (430)/A → C (516)/T → A (558) (stop codon)/T → A (585)/T → C (660)/39bp deletion (341–379) tcdC-A MG675259 7 PC020 G → T (148) tcdC-sc3 MG569922 8 PC021 G → T (148) tcdC-sc3 MG675250 9 PC024 — Wild typea MG596349 10 PC028 — Wild type MG596350 11 PC035 G → T (148) tcdC-sc3 MG655373 12 PC036 G → T (148) tcdC-sc3 MG655374 13 PC049 G → T (148) tcdC-sc3 MG655375 14 PC054 G → T (148) tcdC-sc3 MG675251 15 PC056 G → T (148) tcdC-sc3 MG655376 16 PC062 G → T (53)/A → T (117)/C → T (120)/C → T (183)/C → T (184) (stop codon)/A → G (330)/G → T (430)/A → C (516)/T → A (558) (stop codon)/T → A (585)/T → C (660)/39bp deletion (341–379) tcdC-A MG581978 17 PC063 G → T (148) tcdC-sc3 MG655377 18 PC066 G → T (148) tcdC-sc3 MG675238 19 PC069 G → T (53)/A → T (117)/C → T (120)/C → T (183)/C → T (184) (stop codon)/A → G (330)/G → T (430)/A → C (516)/T → A (558) (stop codon)/T → A (585)/T → C (660)/39bp deletion (341–379) tcdC-A MG675239 20 PC071 G → T (148) tcdC-sc3 MG675240 21 PC074 — Wild type MG675241 22 PC087 G → T (148) tcdC-sc3 MG675242 23 PC089 — Wild type MG675243 24 PC092b — Wild type MG675244 25 PC096 G → T (53)/A → T (117)/C → T (120)/C → T (183)/C → T (184) (stop codon)/A → G (330)/G → T (430)/A → C (516)/T → A (558) (stop codon)/T → A (585)/T → C (660)/39bp deletion (341–379) tcdC-A MG675245 26 PC098 G → T (148) tcdC-sc3 MG675246 27 PC101 G → T (148) tcdC-sc3 MG675247 28 PC103 — Wild type MG675255 29 PC106 G → T (53)/A → T (117)/C → T (120)/C → T (183)/C → T (184) (stop codon)/A → G (330)/G → T (430)/A → C (516)/T → A (558) (stop codon)/T → A (585)/T → C (660)/39bp deletion (341–379) tcdC-A MG675260 30 PC107 — Wild type MG675256 31 PC111 — Wild type MG788278 32 PC112 — Wild type MG788279 33 PC113 — Wild type MG788280 34 PC114 G → T (148) tcdC-sc3 MG788284 35 PC115 G → T (148) tcdC-sc3 MG788285 36 PC116 — Wild type MG788281 37 PC117 — Wild type MG788282 38 PC118 — Wild type MG788283 CPE, cytopathic effects. a Published sequence of Clostridioides difficile strain VPI10463 was used as reference strain for comparison of all sequences [34]. Discussion We found that 5% of patients harboured C. difficile as either toxigenic or nontoxigenic isolates. This proportion is concordant with the previous report from Tehran, Iran, using enzyme-linked immunosorbent assay [21]. Using PCR for detection of tcdA and tcdB, we demonstrated that the majority of C. difficile isolates harboured tcdA and tcdB genes (Table 1). On the other hand, the isolates with no amplicon for tcdA/tcdB were confirmed to be nontoxigenic by a positive assay yielding an amplicon of 769 bp using Lok1 and Lok3 (Table 1) [17]. The frequency of toxigenic isolates tested in the current study (86.36%) was slightly higher than another study (84.2%) reported from Tehran, Iran [22]. In neighbouring countries such as Kuwait, the rate of toxigenic C. difficile was reported to be 0.54% to 64.6% [23], [24]. This difference might be partly related to the sample size, the target population and mainly to the primer set used in the current study. We used the primers targeting the 5′ end of the tcdA gene [15] and amplifying the conserved region and nonrepeating fragment of tcdA. Using this set of primers, all but the nontoxigenic isolates yielded amplicons, and as expected, the negative result for PCR was unlikely unless the isolates had a large deletion in tcdA [15]. Therefore, the isolates harbouring the tcdA gene was subsequently assayed for tcdA deletion in the 3′ end. Analysis of the 3′ end of tcdA revealed that all the isolates except four (PC004, PC008, PC009, PC024) produced an amplicon of 2535 bp using primers NK9-NKV011 (Table 1) [18]. While no amplicon was observed for the latter four isolates in PCR of the 3′ end, the amplicons of 3100 bp were noted using the primers directed at the A3 fragment used for toxinotyping [19]. Altogether, the isolates with a 2535 bp amplicon or 3100 bp were considered ToxA+/ToxB+ (Table 1). Toxinotyping of tcdA- and tcdB-positive isolates showed that these isolates belonged to toxinotype 0 or V. The most predominant toxinotype in our study was toxinotype 0, and this toxinotype showed no changes in tcdA and tcdB gene sequences (Table 1) [19]. Previous studies indicated that the C. difficile isolates with the entire repeating region of tcdA had toxinotype 0 and V [25], [26]. Jalali et al. [27] also found that toxinotype 0 was the prevalent toxinotype in an Iranian hospital. The most frequent toxinotypes in Asia are toxinotype 0 and VIII [24], [28]. Two studies reported that 71.4% and 7.69% of C. difficile toxinotypes in different hospitals in Kuwait and Lebanon belonged to toxinotype 0, respectively [24], [29]. These data show the minor changes in PaLoc either in Iran or Asia. With respect to clinical manifestations, either the nontoxigenic or toxigenic isolates were recovered from symptomatic patients who had diarrhoea. One possible explanation for recovery of the nontoxigenic C. difficile isolates might be the presence of such isolates as a member of intestinal microbiota [30]. In other words, the clinical manifestations may not be associated with the colonization of intestine by C. difficile or its carriage by patients, and only the intake of antibiotics may contribute to the development of antibiotic-associated diarrhoea [31]. For instance, one of the nontoxigenic isolates was recovered from a 54-year-old woman with HIV and toxoplasmosis. This patient was hospitalized for a long period, was subjected to the antimicrobial therapies and finally died. The patient had several predisposing factors, but it is difficult to conclude whether the nontoxigenic isolate was significantly implicated in diarrhoea. Another explanation is that apart from toxins, other virulence factors of C. difficile, particularly the colonization factors, may induce a pathologic response in vulnerable patients [32] and consequently give rise to disease. It has been reported that up to 50% of C. difficile isolated from healthy volunteers and asymptomatic hospitalized patients were nontoxigenic strains. Although there are several case reports describing the possible role of nontoxigenic isolates as risk or protective factor [33], further studies are needed to assess the function of nontoxigenic isolates in inducing C. difficile–associated clinical outcomes. We identified three types of tcdC genes in our isolates using sequencing: wild type, tcdC-A and tcdC-sc3 genotypes. The tcdC-A genotype is characterized by the existence of nonsense mutation at nucleotide 184 and 39 bp deletion at nucleotides 341 to 379 [34]. Toxinotyping revealed that all the isolates that had 39 bp deletion in tcdC gene belonged to toxinotype V, except two isolates. The isolates with no changes in tcdC gene were classified as toxinotype 0 except two isolates that belonged to toxinotype V (Table 1, Table 2). Isolates with TcdC truncation and toxinotype V may cause severe infections in humans and animals and may be identified as hypervirulent strains [35]. Hypervirulent C. difficile strains also express binary toxins (cdtA and cdtB) that may increase the severity of disease [35]. Little is known about the heterogenicity of C. difficile toxin genes in Iranian isolates, especially in Tehran. Jalali et al. [27] found that 0, V and XXIV toxinotypes were predominant in Isfahan. In our study, the six isolates with tcdC-A genotype were also positive for binary toxin (cdtA, cdtB) except one isolate using gene-specific PCR (data not shown). These six cdtA- and cdtB-positive isolates also belonged to toxinotype V. Six isolates of tcdC-A genotype were obtained from hospitalized patients and one from an outpatient (Table 1, Table 2). Jalali et al. [27] also reported that the isolates that possess 39 bp deletion in tcdC gene belonged to toxinotype V isolated from hospitalized patients. Persson et al. [15] and Spigaglia et al. [16] reported that all the isolates that have a 39 bp deletion in tcdC gene may belong to toxinotypes V, VI and VII. Among the tcdC genotypes, the tcdC-sc3 genotype has the highest frequency, as reported in other studies (Table 2) [34,]. This study provides molecular evidence that the isolates with either toxigenic or nontoxigenic profiles are circulating in the healthcare and community settings. Furthermore, it was also demonstrated that the tcdC-A genotype and toxinotype V is not uncommon among Iranian C. difficile isolates. This finding sheds light on the possibility of the contribution of hypervirulent isolates in C. difficile infections in addition to historical isolates of C. difficile. Conflict of interest None declared. Acknowledgement Supported in part by grant 31372 from Tehran University of Medical Sciences and Health Services. ==== Refs References 1 Johnson S. Editorial commentary: changing epidemiology of Clostridium difficile and emergence of new virulent strains Clin Infect Dis 58 2014 1731 1733 24704726 2 Khan F.Y. Elzouki A.N. Clostridium difficile infection: a review of the literature Asian Pac J Trop Med 7 2014 S6 S13 3 Ong G.K. Reidy T.J. Huk M.D. Lane F.R. Clostridium difficile colitis: a clinical review Am J Surg 213 2017 565 571 28131326 4 Bartlett J.G. Clostridium difficile infection Infect Dis Clin North Am 31 2017 489 495 28779831 5 Lewis B.B. Carter R.A. Ling L. Leiner I. Taur Y. Kamboj M. Pathogenicity locus, core genome, and accessory gene contributions to Clostridium difficile virulence mBio 8 2017 e00885–17 6 Voth D.E. Ballard J.D. Clostridium difficile toxins: mechanism of action and role in disease Clin Microbiol Rev 18 2005 247 263 15831824 7 Drudy D. Fanning S. Kyne L. Toxin A–negative, toxin B–positive Clostridium difficile Int J Infect Dis 11 2007 5 10 16857405 8 King A.M. Mackin K.E. Lyras D. Emergence of toxin A–negative, toxin B–positive Clostridium difficile strains: epidemiological and clinical considerations Future Microbiol 10 2015 1 4 25598331 9 Jank T. Belyi Y. Aktories K. Bacterial glycosyltransferase toxins Cell Microbiol 17 2015 1752 1765 26445410 10 Persson S. Jensen J.N. Olsen K.E. Multiplex PCR method for detection of Clostridium difficile tcdA, tcdB, cdtA, and cdtB and internal in-frame deletion of tcdC J Clin Microbiol 49 2011 4299 4300 21976756 11 Fedorko D.P. Williams E.C. Use of cycloserine-cefoxitin-fructose agar and l-proline-aminopeptidase (PRO Discs) in the rapid identification of Clostridium difficile J Clin Microbiol 35 1997 1258 1259 9114419 12 Arroyo L.G. Kruth S.A. Willey B.M. Staempfli H.R. Low D.E. Weese J.S. PCR ribotyping of Clostridium difficile isolates originating from human and animal sources J Med Microbiol 54 2005 163 166 15673511 13 Lemee L. Dhalluin A. Testelin S. Mattrat M.A. Maillard K. Lemeland J.F. Multiplex PCR targeting tpi (triose phosphate isomerase), tcdA (toxin A), and tcdB (toxin B) genes for toxigenic culture of Clostridium difficile J Clin Microbiol 42 2004 5710 5714 15583303 14 Zheng L. Keller S. Lyerly D. Carman R. Genheimer C. Gleaves C. Multicenter evaluation of a new screening test that detects Clostridium difficile in fecal specimens J Clin Microbiol 42 2004 3837 3840 15297543 15 Persson S. Torpdahl M. Olsen K. New multiplex PCR method for the detection of Clostridium difficile toxin A (tcdA ) and toxin B (tcdB ) and the binary toxin (cdtA/cdtB ) genes applied to a Danish strain collection Clin Microbiol Infect 14 2008 1057 1064 19040478 16 Spigaglia P. Mastrantonio P. Molecular analysis of the pathogenicity locus and polymorphism in the putative negative regulator of toxin production (TcdC) among Clostridium difficile clinical isolates J Clin Microbiol 40 2002 3470 3475 12202595 17 Braun V. Hundsberger T. Leukel P. Sauerborn M. von Eichel-Streiber C. Definition of the single integration site of the pathogenicity locus in Clostridium difficile Gene 181 1996 29 38 8973304 18 Kato H. Kato N. Katow S. Maegawa T. Nakamura S. Lyerly D.M. Deletions in the repeating sequences of the toxin A gene of toxin A–negative, toxin B–positive Clostridium difficile strains FEMS Microbiol Lett 175 1999 197 203 10386368 19 Rupnik M. Avesani V. Janc M. von Eichel-Streiber C. Delmée M. A novel toxinotyping scheme and correlation of toxinotypes with serogroups of Clostridium difficile isolates J Clin Microbiol 36 1998 2240 2247 9665999 20 Barbut F. Kajzer C. Planas N. Petit J.C. Comparison of three enzyme immunoassays, a cytotoxicity assay, and toxigenic culture for diagnosis of Clostridium difficile –associated diarrhea J Clin Microbiol 31 1993 963 967 8463404 21 Nazemalhosseini-Mojarad E. Azimirad M. Razaghi M. Torabi P. Moosavi A. Alebouyeh M. Frequency of Clostridium difficile among patients with gastrointestinal complaints Gastroenterol Hepatol Bed Bench 4 2011 210 24834184 22 Shayganmehr F.S. Alebouyeh M. Azimirad M. Aslani M.M. Zali M.R. Association of tcdA + /tcdB + Clostridium difficile genotype with emergence of multidrug-resistant strains conferring metronidazole resistant phenotype Iran Biomed 19 2015 143 23 Jamal W. Pauline E. Rotimi V. A prospective study of community-associated Clostridium difficile infection in Kuwait: epidemiology and ribotypes Anaerobe 35 2015 28 32 24 Jamal W. Rotimi V. Grubesic A. Rupnik M. Brazier J. Duerden B. Correlation of multidrug resistance, toxinotypes and PCR ribotypes in Clostridium difficile isolates from Kuwait J Chemother 21 2009 521 526 19933043 25 Kim S.J. Kim H. Seo Y. Yong D. Jeong S.H. Chong Y. Molecular characterization of toxin A–negative, toxin B–positive variant strains of Clostridium difficile isolated in Korea Diagn Microbiol Infect Dis 67 2010 198 201 20338708 26 Rupnik M. Kato N. Grabnar M. Kato H. New types of toxin A–negative, toxin B–positive strains among Clostridium difficile isolates from Asia J Clin Microbiol 41 2003 1118 1125 12624039 27 Jalali M. Khorvash F. Warriner K. Weese J.S. Clostridium difficile infection in an Iranian hospital BMC Res Notes 5 2012 159 22436392 28 Rupnik M. Janezic S. An update on Clostridium difficile toxinotyping J Clin Microbiol 54 2016 13 18 26511734 29 Moukhaiber R. Araj G.F. Kissoyan K.A.B. Cheaito K.A. Matar G.M. Prevalence of Clostridium difficile toxinotypes in infected patients at a tertiary care center in Lebanon J Infect Dev Ctries 9 2015 732 735 26230123 30 Stojanovic P. Kocic B. Stojanovic M. Miljkovic-Selimovic B. Tasic S. Miladinovic-Tasic N. Clinical importance and representation of toxigenic and non-toxigenic Clostridium difficile cultivated from stool samples of hospitalized patients Braz J Microbiol 43 2012 215 223 24031820 31 Thomas C. Stevenson M. Riley T.V. Antibiotics and hospital-acquired Clostridium difficile –associated diarrhoea: a systematic review J Antimicrob Chemother 51 2003 1339 1350 12746372 32 Vedantam G. Clark A. Chu M. McQuade R. Mallozzi M. Viswanathan V. Clostridium difficile infection: toxins and non-toxin virulence factors, and their contributions to disease establishment and host response Gut Microbe 7 2012 10 33 Natarajan M. Walk S.T. Young V.B. Aronoff D.M. A clinical and epidemiological review of non-toxigenic Clostridium difficile Anaerobe 22 2013 1 5 23727391 34 Curry S.R. Marsh J.W. Muto C.A. O’Leary M.M. Pasculle A.W. Harrison L.H. tcdC genotypes associated with severe TcdC truncation in an epidemic clone and other strains of Clostridium difficile J Clin Microbiol 45 2007 215 221 17035492 35 Goldenberg S.D. French G.L. Lack of association of tcdC type and binary toxin status with disease severity and outcome in toxigenic Clostridium difficile J Infect 62 2011 355 362 21396957